Cleared Traditional

K142304 - Viberect Penile Vibratory Stimulation Device (FDA 510(k) Clearance)

Class II Obstetrics & Gynecology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2014
Decision
46d
Days
Class 2
Risk

K142304 is an FDA 510(k) clearance for the Viberect Penile Vibratory Stimulation Device. Classified as Vibrator For Therapeutic Use, Genital (product code KXQ), Class II - Special Controls.

Submitted by Reflexonic, LLC (Frederick, US). The FDA issued a Cleared decision on October 3, 2014 after a review of 46 days - a notably fast clearance cycle.

This device falls under the Obstetrics & Gynecology FDA review panel, regulated under 21 CFR 884.5960 - the FDA obstetrics and gynecology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Reflexonic, LLC devices

Submission Details

510(k) Number K142304 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 18, 2014
Decision Date October 03, 2014
Days to Decision 46 days
Submission Type Traditional
Review Panel Obstetrics & Gynecology (OB)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
114d faster than avg
Panel avg: 160d · This submission: 46d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code KXQ Vibrator For Therapeutic Use, Genital
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 884.5960
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Obstetrics & Gynecology devices follow this clearance model.